B CELL LEUKEMIA
Clinical trials for B CELL LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new B CELL LEUKEMIA trials appear
Sign up with your email to follow new studies for B CELL LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Targeting CAR T-Cells offer new hope for kids with relapsed leukemia
Disease control Recruiting nowThis study tests a new treatment for children and young adults (ages 3-39) with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 …
Matched conditions: B CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:48 UTC
-
Next-gen CART therapy targets stubborn leukemia that evades first-line treatment
Disease control Recruiting nowThis study tests a new type of CART immunotherapy for people with B-cell acute lymphoblastic leukemia (ALL) whose cancer cells do not have the CD19 marker, either from the start or after previous CD19-targeted CART therapy. The treatment uses a patient's own immune cells, modifie…
Matched conditions: B CELL LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CLIC-2201 for people with B-cell blood cancers that have come back or stopped responding to standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells…
Matched conditions: B CELL LEUKEMIA
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 02, 2026 11:40 UTC
-
Leukemia treatment may weaken vaccine protection – study seeks answers
Knowledge-focused Recruiting nowThis study looks at whether children and young adults (up to age 21) who received blinatumomab for B-cell acute lymphoblastic leukemia still have protection from their routine childhood vaccines. Researchers will test antibody levels for diseases like tetanus, hepatitis B, and me…
Matched conditions: B CELL LEUKEMIA
Sponsor: Arkansas Children's Hospital Research Institute • Aim: Knowledge-focused
Last updated Jun 09, 2026 12:06 UTC